翻訳と辞書
Words near each other
・ Nipradilol
・ NIPRNet
・ Nipro
・ NIPS
・ NIPS School of Hotel Management
・ Nipsai
・ Nipsan language
・ Nipsey Hussle
・ Nipsey Hussle discography
・ Nipsey Russell
・ Nipsie
・ Nipsistiarios
・ Nipson anomemata me monan opsin
・ Nipster
・ NIPT
NIPTE
・ Niptera
・ Nipterella
・ Nipteria
・ Nipton, California
・ Niptus
・ Nipun Akter
・ Nipuna Bandara
・ Niq
・ Niq Mhlongo
・ Niqiu
・ Niqmaddu II
・ Niqmepa
・ Niqmepa, King of Alalakh
・ Niqmi-Epuh


Dictionary Lists
翻訳と辞書 辞書検索 [ 開発暫定版 ]
スポンサード リンク

NIPTE : ウィキペディア英語版
NIPTE

The National Institute for Pharmaceutical Technology and Education (NIPTE) is a non-profit scientific and research and development organization that was established in 2005 and incorporated in June 2007 in the State of Indiana. Its offices are currently located in Rosemont, IL.
NIPTE’s current membership includes 12 leading schools and colleges of pharmacy and chemical engineering from the following universities: Duquesne University, Illinois Institute of Technology, Purdue University, Rutgers University, University of Puerto Rico, University of Connecticut, University of Iowa, University of Kentucky, University of Maryland, University of Michigan, University of Minnesota and the University of Wisconsin.
==Pharmaceutical manufacturing challenge==
The pharmaceutical industry is currently facing increased pricing pressures globally and rising manufacturing costs. Cost of Goods (COGS) for Brand-Name pharmaceutical drugs can be higher than 30% of the total sales revenues of these companies. In comparison, the percentage of sales revenues spent on R&D by these pharmaceutical companies is only 10-15%. For generic drugs, COGS can be as high as 50% of their total sales revenues. Traditionally, pharmaceutical companies preferred to manufacture their own products internally. They were keen on “making” what they “sold” because it provided them with more control of the quality of their products. However, since the pressures to reduce cost these days are high, to save money, the pharmaceutical industry is increasingly outsourcing manufacturing to countries in Asia – where the regulatory standards are evolving and sometimes could lag several years behind the U.S.
The science required to transform a new discovery to a marketable new drug has definitely not kept pace with advances on the drug discovery side. Pharmaceutical product development today is more of an art than science. Once the new drug discovery is made, product development and manufacturing are left to traditional “tried and true” practices. Marked advances in chemistry, chemical engineering, computer modeling & simulation, instrumentation, analytical science, and product formulations that could be used to increase efficiency may also be more gainfully applied in pharmaceutical product development and manufacturing. The cost savings achievable by outsourcing can be easily exceeded by improving the science and technology for developing and manufacturing pharmaceutical products. Other industries, such as the semiconductor industry have examined their manufacturing technologies and have modernized them. This has allowed these industries to become more competitive and to have products of superior value.
Manufacturing is a critical step in the chain of very complex events before a drug reaches the pharmacy shelves. When that critical link is broken, it opens the door for something like the heparin crisis. And heparin may just be the tip of the iceberg. The ultimate answer is not costly inspections of foreign manufacturing sites. If that remains the answer, the U.S. Food and Drug Administration (FDA) will need a lot more resources and millions of dollars from the United States Congress to ensure that all drugs and drug components manufactured in foreign countries are safe and effective. Our goal should be to improve the quality of pharmaceutical manufacturing such that drugs can be produced safely and cost-effectively no matter where they are produced. We need to build in manufacturing quality with front-end design – not back-end inspection. If the U.S. wants to increase medication safety and reduce the cost of drugs, it must invest in the basic science of drug development and manufacturing.
The (public/private partnership model ) for drug discovery (known as the (NIH Roadmap )) shows success by spurring advances with strong basic science research investment. Between 1999 and 2006, research and development investments in the United States grew 5 times the initial investment while in Europe it grew 2.9 times. However, since 2006 Asia has markedly outpaced the U.S. in the opening of new research sites for pharmaceuticals.

抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)
ウィキペディアで「NIPTE」の詳細全文を読む



スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース

Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.